MX2012003287A - Uso de la identificacion microambiental de sparc en el tratamiento del cancer. - Google Patents

Uso de la identificacion microambiental de sparc en el tratamiento del cancer.

Info

Publication number
MX2012003287A
MX2012003287A MX2012003287A MX2012003287A MX2012003287A MX 2012003287 A MX2012003287 A MX 2012003287A MX 2012003287 A MX2012003287 A MX 2012003287A MX 2012003287 A MX2012003287 A MX 2012003287A MX 2012003287 A MX2012003287 A MX 2012003287A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
sparc microenvironment
microenvironment signature
sparc
Prior art date
Application number
MX2012003287A
Other languages
English (en)
Inventor
Vuong Trieu
Neil Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2012003287A publication Critical patent/MX2012003287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La invención proporciona técnicas basadas en el anticuerpo anti-SPARC multiparamétricos para predecir la respuesta a una terapia, incluyendo quimioterapia, radioterapia, terapia quirúrgica y terapias combinadas.
MX2012003287A 2009-09-18 2010-09-20 Uso de la identificacion microambiental de sparc en el tratamiento del cancer. MX2012003287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27696909P 2009-09-18 2009-09-18
PCT/US2010/049545 WO2011035274A1 (en) 2009-09-18 2010-09-20 Use of the sparc microenvironment signature in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2012003287A true MX2012003287A (es) 2012-08-03

Family

ID=43759058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003287A MX2012003287A (es) 2009-09-18 2010-09-20 Uso de la identificacion microambiental de sparc en el tratamiento del cancer.

Country Status (13)

Country Link
US (1) US20120245089A1 (es)
EP (1) EP2478362B1 (es)
JP (1) JP2013505268A (es)
KR (1) KR20120092597A (es)
CN (1) CN102576016A (es)
AU (1) AU2010295324B2 (es)
BR (1) BR112012008316A2 (es)
CA (1) CA2774550A1 (es)
IL (1) IL218642A0 (es)
MX (1) MX2012003287A (es)
NZ (1) NZ598801A (es)
WO (1) WO2011035274A1 (es)
ZA (1) ZA201202657B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1014392A2 (pt) * 2009-05-28 2016-04-05 Abraxis Biosciense Llc uso de anticorpos anti-sparc para prever resposta a quimioterapia
KR20130086546A (ko) * 2010-06-03 2013-08-02 아브락시스 바이오사이언스, 엘엘씨 암 치료에 있어 ｓｐａｒｃ 미세환경 시그니처의 용도
US11017533B2 (en) * 2016-11-10 2021-05-25 Hoffmann-La Roche Inc. Distance-based tumor classification

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5003621A (en) 1989-11-02 1991-03-26 Motorola, Inc. Direct conversion FM receiver
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
EP1604014A4 (en) * 2003-03-20 2008-03-26 Dana Farber Cancer Inst Inc GENE EXPRESSION IN BREAST CANCER
CN105316405A (zh) * 2003-07-17 2016-02-10 环太平洋生物技术有限公司 用于胃癌检测的标记物
JP4682152B2 (ja) * 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
GB0417740D0 (en) * 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
DE602005016831D1 (es) * 2004-10-19 2009-11-05 Univ Kumamoto
JP2008535475A (ja) * 2005-02-18 2008-09-04 アブラクシス バイオサイエンス、インコーポレイテッド Ｑ３ｓｐａｒｃ欠失変異体及びその使用
CA3054535A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX2008015939A (es) * 2006-06-16 2009-02-11 Univ Kumamoto Peptidos antigeneticos de rechazo de tumor derivados de sparc y medicamentos que comprenden los mismos.
JP5933893B2 (ja) * 2006-12-14 2016-06-15 アブラクシス バイオサイエンス， エルエルシー ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
AU2008226283A1 (en) * 2007-03-09 2008-09-18 The University Of British Columbia Assessing chemotherapy resistance of colorectal tumors by determining sparc hypermethylation
ES2389828T3 (es) * 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物

Also Published As

Publication number Publication date
AU2010295324A1 (en) 2012-04-05
KR20120092597A (ko) 2012-08-21
JP2013505268A (ja) 2013-02-14
WO2011035274A1 (en) 2011-03-24
EP2478362A4 (en) 2013-09-11
BR112012008316A2 (pt) 2017-06-06
CN102576016A (zh) 2012-07-11
AU2010295324B2 (en) 2015-04-30
ZA201202657B (en) 2013-09-25
CA2774550A1 (en) 2011-03-24
EP2478362B1 (en) 2016-05-11
EP2478362A1 (en) 2012-07-25
US20120245089A1 (en) 2012-09-27
IL218642A0 (en) 2012-05-31
NZ598801A (en) 2014-07-25

Similar Documents

Publication Publication Date Title
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
UA109271C2 (uk) Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
PH12018502569A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
MX2010006991A (es) Tratamientos de cancer terapeuticos.
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
IN2014MN01945A (es)
IL207310A0 (en) Vaccine compositions
MX2015001551A (es) Compuestos y composiciones activadoras de enzima.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
MX2012003287A (es) Uso de la identificacion microambiental de sparc en el tratamiento del cancer.
WO2011153485A3 (en) Use of the sparc microenvironment signature in the treatment of cancer
MX2015006096A (es) Leucocitos como celulas de administracion para imagen y terapia de enfermedad.
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
WO2012058462A3 (en) Combination therapy for the treatment of cancer
UA35392U (ru) Способ комплексной терапии злокачественных опухолей и метастазов
UA29209U (ru) Способ хирургического лечения рака молочной железы

Legal Events

Date Code Title Description
FA Abandonment or withdrawal